Please assess the completion status of the following clinical trial:

Trial Title: Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion~* All patients with HCV virus infection documented by detectable plasma HCV antibodies and RNA who would be excluded by FDA criteria for antiviral treatment with peginterferon-alpha 2a and ribavirin due to thrombocytopenia (platelets \< 70,000/L); patients cannot have received previous anti-viral therapy with interferon/ribavirin~* Liver biopsy indicating chronic hepatitis within the previous 2 years~* Mean platelet count of \< 70,000/L on two repeated measurements in a two week screening period with no single count \>= 75,000/L~* Neutrophil count of \>= 1000/mcl~* Hemoglobin \>= 11gm/dL and no evidence of active bleeding~* Prothrombin Time (PT) INR \< 1.6 seconds~* Albumin \>= 2.5 gm/dL~* ALT \>= 1.2 and \< 10 times upper limit of normal~* No evidence of either ischemic change or cardiac injury on 12-lead electrocardiogram (EKG)~* Negative pregnancy test and women must be using adequate contraception for at least 2 weeks prior to enrollment and while enrolled in the study~* Signed informed consent within 2 weeks of enrollment and randomization~Exclusion~* Received previous anti-viral therapy with interferon/ribavirin~* Child's Class B and C or acute decompensated liver disease~* Human Immunodeficiency Virus (HIV) infection or co-infected with hepatitis B virus~* Any untreated active infection~* Active malignancy, known primary bone marrow disorder (myelodysplasia, myeloproliferative disease, etc.), or history of blood or bone marrow transplantation; patients with documented hemoglobinopathies~* Active vasculitis associated with cryoglobulinemia as manifested by either renal disease or dermatologic findings~* Positive pregnancy test or men with pregnant partners~* Creatinine and BUN of greater than twice (2x) the upper limits of normal~* History of venous or arterial thrombosis, myocardial infarction or thrombotic stroke~* Patients who in the investigators opinion will fail to be compliant or have other contraindication to treatment on this study~* Other inherited or acquired liver disease~* Previous solid organ transplant~* Known hypersensitivity to E. coli derived recombinant proteins~* Active rheumatologic disease including Systemic Lupus Erythematosis~* Known history of Disseminated Intravascular Coagulation, Hemolytic Uremic Syndrome, or Thrombotic Thrombocytopenic Purpura

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients receive romiplostim subcutaneously once weekly for 8 weeks in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive placebo subcutaneously once weekly for 8 weeks. Patients failing to achieve a platelet count of \&gt; 100,000/L cross over to arm I.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval